McKesson Corp (MCK) Receives Overweight Rating from Barclays
Barclays initiates coverage on McKesson Corp (MCK) with an Overweight rating.
McKesson Corp. engages in providing healthcare services. The company is headquartered in Irving, Texas and currently employs 43,000 full-time employees. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. The company also offers oncology and specialty solutions.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for McKesson Corp.
Last Updated: Dec 11, 2025, 11:04 PM · Source: Finnhub.io
Barclays initiates coverage on McKesson Corp (MCK) with an Overweight rating.
McKesson Corp (MCK) has announced a quarterly dividend of $0.82 per share.
McKesson Corp (MCK) exceeded Q2 2026 earnings expectations with EPS of $9.86.